Human Metabolome TechnologiesTSE:6090 +0.84%59 Shareholder Yield % is 5.79% as of Dec. 2025, which is 6333% above its 10-year median of 0.09. GuruFocus rates TSE:6090 with a GF Score™ of 59/100 and a GF Value™ of 円529.55 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 85.78% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Human Metabolome Technologies's Shareholder Yield % was 5.79%.
Human Metabolome Technologies (TSE:6090) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Human Metabolome Technologies Shareholder Yield % Related Terms
Human Metabolome Technologies Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies Shareholder Yield % Chart
TSE:6090 vs TMO, DHR, IDXX: Shareholder Yield % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Shareholder Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Human Metabolome Technologies (TSE:6090) has a Shareholder Yield % of 5.79% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Human Metabolome Technologies and its competitors. This is 6333% above median its historical median of 0.09. According to the industry distribution chart, Human Metabolome Technologies ranks #29 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 14.2%.
Is Human Metabolome Technologies' Shareholder Yield % too high?
Human Metabolome Technologies' current Shareholder Yield % of 5.79% is 6333% above median its 10-year median of 0.09. Based on the distribution chart, Human Metabolome Technologies ranks #29 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Shareholder Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #29 out of 204 companies for Shareholder Yield %. This places Human Metabolome Technologies in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Diagnostics & Research company?
A good Shareholder Yield % depends on the Medical Diagnostics & Research industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current Shareholder Yield % is 5.79%, which is 6333% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円529.55, compared to a current price of 円598.00 — trading 12.9% above its estimated fair value. The current Shareholder Yield % is 5.79%, which is 6333% above median its 10-year median of 0.09. Human Metabolome Technologies' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Shareholder Yield % is 5.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued.
The current stock price of 円598.00 is trading 12.9% above its estimated GF Value™ of 円529.55.
GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.
Key valuation signals for TSE:6090:
Shareholder Yield %: 5.79% (6333% above median its 10-year median of 0.09)
GF Value™: 円529.55 vs. price of 円598.00 (12.9% above fair value)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Human Metabolome Technologies Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
